These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 25698368)

  • 1. Successful multi-target therapy using corticosteroid, tacrolimus, cyclophosphamide, and rituximab for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis.
    Watanabe R; Ishii T; Araki K; Ishizuka M; Kamogawa Y; Fujita Y; Shirota Y; Fujii H; Harigae H
    Mod Rheumatol; 2016; 26(3):465-6. PubMed ID: 25698368
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment with tacrolimus of progressive interstitial pneumonia associated with amyopathic dermatomyositis refractory to cyclosporine.
    Ando M; Miyazaki E; Yamasue M; Sadamura Y; Ishii T; Takenaka R; Ito T; Nureki S; Kumamoto T
    Clin Rheumatol; 2010 Apr; 29(4):443-5. PubMed ID: 20130943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of calcineurin inhibitors for the treatment of interstitial lung disease associated with polymyositis/dermatomyositis.
    Kurita T; Yasuda S; Amengual O; Atsumi T
    Lupus; 2015 Jan; 24(1):3-9. PubMed ID: 25297551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment.
    Koichi Y; Aya Y; Megumi U; Shunichi K; Masafumi S; Hiroaki M; Masahiko K; Shinsuke K; Manabu U; Kenichiro H; Fumiaki A; Nozomi A; Toshitaka M; Masayoshi Y; Chikako K; Yoshinao M; Tatsuo S; Masahiko K
    Mod Rheumatol; 2017 May; 27(3):536-540. PubMed ID: 25698373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between disease activity and serum ferritin in clinically amyopathic dermatomyositis with rapidly-progressive interstitial lung disease: a case report.
    Yamada K; Asai K; Okamoto A; Watanabe T; Kanazawa H; Ohata M; Ohsawa M; Hirata K
    BMC Res Notes; 2018 Jan; 11(1):34. PubMed ID: 29338781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful multi-target therapy including rituximab and mycophenolate mofetil in anti-melanoma differentiation-associated gene 5 antibody-positive rapidly progressive interstitial lung disease with clinically amyopathic dermatomyositis.
    Hisanaga J; Kotani T; Fujiki Y; Yoshida S; Takeuchi T; Makino S
    Int J Rheum Dis; 2017 Dec; 20(12):2182-2185. PubMed ID: 28752606
    [No Abstract]   [Full Text] [Related]  

  • 7. Mycophenolate mofetil therapy for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis.
    Tsuchiya H; Tsuno H; Inoue M; Takahashi Y; Yamashita H; Kaneko H; Kano T; Mimori A
    Mod Rheumatol; 2014 Jul; 24(4):694-6. PubMed ID: 24506658
    [No Abstract]   [Full Text] [Related]  

  • 8. Cyclophosphamide pulse therapy for rapidly progressive interstitial pneumonia in dermatomyositis. A new possibility for rescue?
    Takizawa H; Ito K
    Intern Med; 1997 Jul; 36(7):448-9. PubMed ID: 9240490
    [No Abstract]   [Full Text] [Related]  

  • 9. A case of hypomyopathic dermatomyositis associated with rapid progressive interstitial pneumonia resistant to multi-immunosuppressive therapy.
    Tsuda T; Asanuma Y; Koyama S; Kawabata Y; Moriguchi M
    Am J Med Sci; 2007 Mar; 333(3):185-90. PubMed ID: 17496740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis.
    Ochi S; Nanki T; Takada K; Suzuki F; Komano Y; Kubota T; Miyasaka N
    Clin Exp Rheumatol; 2005; 23(5):707-10. PubMed ID: 16173253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Serum Ferritin Level Is Associated with the Treatment Responsivity for Rapidly Progressive Interstitial Lung Disease with Amyopathic Dermatomyositis, Irrespective of the Anti-MDA5 Antibody Level.
    Osawa T; Morimoto K; Sasaki Y; Matsuda S; Yamana K; Yano R; Uchiyama T; Goto H
    Intern Med; 2018 Feb; 57(3):387-391. PubMed ID: 29093381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycobacterium avium complex-induced pleurisy in a patient with amyopathic dermatomyositis and interstitial lung disease after prolonged immunosuppressive therapy.
    Lee HT; Su WJ; Chou TY; Chen WS; Su KY; Huang DF
    J Clin Rheumatol; 2009 Jun; 15(4):193-4. PubMed ID: 19455058
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-MDA5 Antibody-positive Dermatomyositis Complicated by Autoimmune-associated Hemophagocytic Syndrome That Was Successfully Treated with Immunosuppressive Therapy and Plasmapheresis.
    Fujita Y; Fukui S; Suzuki T; Ishida M; Endo Y; Tsuji S; Takatani A; Igawa T; Shimizu T; Umeda M; Sumiyoshi R; Nishino A; Koga T; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Abe K; Kawakami A
    Intern Med; 2018 Dec; 57(23):3473-3478. PubMed ID: 29984753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis.
    Matsushita T; Mizumaki K; Kano M; Yagi N; Tennichi M; Takeuchi A; Okamoto Y; Hamaguchi Y; Murakami A; Hasegawa M; Kuwana M; Fujimoto M; Takehara K
    Br J Dermatol; 2017 Feb; 176(2):395-402. PubMed ID: 27452897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of clinically amyopathic dermatomyositis despite aggressive immunosuppression with cyclophosphamide and prednisone.
    Hildebrand BA; Arroyo R
    J Clin Rheumatol; 2010 Apr; 16(3):143-5. PubMed ID: 20216327
    [No Abstract]   [Full Text] [Related]  

  • 16. Dermatomyositis with Rapidly Progressive Interstitial Lung Disease Treated with Rituximab: A Report of 3 Cases in Japan.
    Tokunaga K; Hagino N
    Intern Med; 2017; 56(11):1399-1403. PubMed ID: 28566605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease.
    Romero-Bueno F; Diaz Del Campo P; Trallero-Araguás E; Ruiz-Rodríguez JC; Castellvi I; Rodriguez-Nieto MJ; Martínez-Becerra MJ; Sanchez-Pernaute O; Pinal-Fernandez I; Solanich X; Gono T; Gonzalez-Gay MA; Plana MN; Selva-O'Callaghan A;
    Semin Arthritis Rheum; 2020 Aug; 50(4):776-790. PubMed ID: 32534273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapidly progressive interstitial lung disease in a patient with anti-MDA5-positive amyopathic dermatomyositis.
    Nandy A; Gaïni S; Sore P
    Scand J Rheumatol; 2018 Jul; 47(4):334-335. PubMed ID: 29043891
    [No Abstract]   [Full Text] [Related]  

  • 19. Cutaneous amyloidosis associated with amyopathic dermatomyositis.
    Taniguchi Y; Horino T; Terada Y
    J Rheumatol; 2009 May; 36(5):1088-9. PubMed ID: 19435977
    [No Abstract]   [Full Text] [Related]  

  • 20. Dramatic improvement of anti-SS-A/Ro-associated interstitial lung disease after immunosuppressive treatment.
    Paola C; Giuliana F; Giovanni O; Cristian C; Domenico B
    Rheumatol Int; 2016 Jul; 36(7):1015-21. PubMed ID: 27021338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.